SEC Tracker
Get the app

Jazz Pharmaceuticals JAZZ

Jazz Pharmaceuticals reported a $483.4 million net loss for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $1.24 billion for the three months ended Sep 30, 2026
  2. Net loss of $483.4 million for the three months ended Sep 30, 2026
  3. Diluted EPS of -$7.48 for the three months ended Sep 30, 2026
  4. Cash and equivalents of $2.04 billion as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Jazz Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Repligen RGEN public float $6.0B, Jun 30, 2025
  3. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.